Financial

News

e-therapeutics' chief executive Ali Mortazavi

e-therapeutics is latest UK biotech to seek AIM de-listing

e-therapeutics has become the latest UK biotech to say it plans to delist from the Alternative Investment Market (AIM) in another blow to the reputation of the London Stoc

News

Acorda filed for bankruptcy, and Merz is eyeing its assets

Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Mer

News

Redx joins C4X in delisting from AIM due to liquidity issues

UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of

News

Bayer CEO pulls back from breakup of ‘badly broken’ group

Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati

News

Astellas raises Padcev forecasts on bladder cancer data

Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m

News

AbbVie’s new drugs keep post-Humira prospects on track

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th

e-therapeutics is latest UK biotech to seek AIM de-listing

Acorda filed for bankruptcy, and Merz is eyeing its assets

Redx joins C4X in delisting from AIM due to liquidity issues

Bayer CEO pulls back from breakup of ‘badly broken’ group

Astellas raises Padcev forecasts on bladder cancer data

AbbVie’s new drugs keep post-Humira prospects on track

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Financial

Editor's Picks